Alprostadil vs Kisspeptin-10
A side-by-side research comparison of Alprostadil and Kisspeptin-10 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Alprostadil | Kisspeptin-10 |
|---|---|---|
| Full name | Alprostadil (Prostaglandin E1) | Kisspeptin-10 (Metastin 45-54) |
| Category | Sexual Health | Sexual Health |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Alprostadil activates prostaglandin receptors that raise intracellular cAMP in cavernosal smooth muscle, causing vasodilation and increased blood inflow to produce an erection regardless of nerve signaling or arousal. | Binds KISS1R on GnRH neurons, stimulating GnRH pulsatile release for LH/FSH secretion. Also enhances limbic sexual arousal circuits. |
| Molecular weight | 354.5 Da | 1,302 Da |
| Half-life | Very short (minutes, locally metabolized) | 4-6 min (IV) / 20-30 min (SubQ) |
| Bioavailability | Intracavernosal injection or intraurethral suppository | High (IV/SubQ) |
| Typical dose | Provider-titrated per response | 1-10 nmol/kg |
| Frequency | As needed before activity | Single dose or daily |
| Route | Intracavernosal injection or urethral pellet | IV or Subcutaneous |
Alprostadil reported benefits
- Effective for erectile dysfunction
- Works independent of arousal
- Rapid onset
- Useful when oral PDE5 inhibitors fail
Kisspeptin-10 reported benefits
- Stimulates GnRH naturally
- Increases LH and testosterone
- Enhances sexual arousal (fMRI data)
- Potential fertility aid
- HPG axis diagnostic tool
Related comparisons
Research and educational reference only. Not medical advice.